MimiVax is commercializing intellectual property developed at Roswell Park Cancer Institute (RPCI) through bench to bedside clinical translation. We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is our lead drug pipeline agent.
SurVaxM is a cancer vaccine that stimulates a potent immune response to the survivin molecule, an important cellular protein thought to sustain the viability of tumor cells. Studies of the vaccine have shown that it substantially prolongs survival in pre-clinical models of brain, ovarian, renal and prostate cancers.
MimiVax has completed the first phase I clinical trial of SurVaxM in recurrent glioma. SurVaxM was found to be safe and well-tolerated in patients. A phase II clinical trial in newly diagnosed glioblastoma is now open. MimiVax intends to develop SurVaxM through clinical trials to deliver more effective immunological cancer therapies to patients.
To learn more about the vaccine, we encourage you to reach out to us via our contact form or give us a call at 716-845-8850 today.